Even though this is interesting, it
still does not tell us why many doctors are not using metformin as
the first-line treatment for type 2 diabetes. The results of a new
US study show that only 58% of individuals with type 2 diabetes were
started on metformin as their first oral glucose-lowering medication.
This is despite the fact that this drug is widely recommended as the
initial therapy of choice in numerous diabetes guidelines.
I can say that insulin can be an
excellent choice when the doctors have waited too long to diagnose
type 2 diabetes, but this isn't even mentioned in the people
receiving other medications. All were
other oral medications -
sulfonylureas, thiazolidinediones, and dipeptidyl peptidase 4 (DPP-4)
inhibitors. The Study period was from July 2009 to end of June 2013
and who filled a second prescription for a medication in the same
class within 90 days of the first.
Senior author Dr Niteesh K Choudhry,
from the division of pharmacoepidemiology at Harvard Medical School,
Boston, MA explained it this way, "These findings have
significant implications for quality of life and medication costs."
In an accompanying commentary, Drs
Jodi B Segal and Nisa M Maruther (Johns Hopkins University School of
Medicine, Baltimore, Maryland) agree with these conclusions. "This
meticulously conducted study… adds modestly to what is already
known on this topic. First-line therapy should be metformin in
patients without contraindications."
“Without contraindications”
is the key and this, along with quality of life and medication costs
are the reasons for metformin being considered in first-line therapy.
Occasionally some doctors are persuaded by drug representatives to
use other medications and money may be the reason these doctors start
with the more expensive drugs.
Dr. Choudhry stated, “Although the
study did not examine the specific prescribers involved, with this
type of national insurer the "vast majority" of physicians
would have been primary-care providers (general internists) seeing
patients in routine care settings.”
A total of 15 516 patients were said to
have met the inclusion criteria, of whom 8964 (57.8%) started therapy
with metformin. Sulfonylurea treatment was the first drug in 23% of
cases, 6.1% began treatment with thiazolidinediones, and 13.1% with
DPP-4 inhibitors.
“Patients prescribed metformin
were less likely to require treatment intensification compared with
those who used the other medications: 24.5% who started on metformin
required a second oral medication, compared with 37.1% of patients
prescribed a sulfonylurea, 39.6% who began with a thiazolidinedione,
and 36.2% given a DPP-4 inhibitor first. Sulfonylureas, in
particular, were associated with more adverse cardiovascular events
and hypoglycemia.”
I am aware of many patients that are
started on metformin, extended release (ER), that have been doing
well because they followed directions and consumed it with food or at
meal time and had few of the gastrointestinal problems. Others have
started on regular metformin and have encountered the
gastrointestinal discomfort. Most are okay in a few weeks and a few
have been unable to tolerate this. I don't know anyone using the
liquid metformin, but it is available.
In addition to the above link, this
topic has received wide press. One more link if you are interested is this by
Healio Endocrine Today.